Stereotactic Radiotherapy nAMD: Improvements Needed
Table of Contents
As of July 7, 2025, the landscape of neovascular age-related macular degeneration (nAMD) treatment is undergoing a notable shift, driven by promising research into stereotactic radiotherapy (SRT). While anti-VEGF injections remain the standard of care, the recent STAR trial has ignited considerable interest in SRT as a potential option or adjunct therapy. This article provides a comprehensive overview of SRT for nAMD,exploring its mechanisms,clinical trial results,potential benefits,risks,and future directions,establishing a foundational resource for both clinicians and patients.
Age-related macular degeneration (AMD) is a leading cause of vision loss in individuals over 50. It exists in two primary forms: dry AMD and wet AMD, also known as neovascular AMD (nAMD). This discussion focuses specifically on nAMD.
What is nAMD? Neovascular AMD occurs when abnormal blood vessels grow beneath the retina. These vessels leak fluid and blood, causing distortion and eventual damage to the macula, the central part of the retina responsible for sharp, central vision.
Current treatment Landscape: The current standard of care for nAMD involves regular intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drugs. These medications inhibit the growth of new blood vessels, slowing disease progression and, in some cases, improving vision.
Limitations of Anti-VEGF Therapy: While effective, anti-VEGF therapy has limitations. These include the need for frequent injections, the potential for treatment resistance, and the risk of complications such as endophthalmitis (infection inside the eye).The treatment burden and cost associated with lifelong injections are also significant concerns.
Introducing stereotactic Radiotherapy (SRT) For nAMD
Stereotactic radiotherapy (SRT) is a highly precise form of radiation therapy that delivers a focused dose of radiation to a specific target. In the context of nAMD, SRT aims to reduce the activity of abnormal blood vessels by inhibiting their growth and reducing leakage.
How Does SRT Work? SRT utilizes advanced imaging techniques, such as computed tomography (CT) scans, to precisely locate the abnormal blood vessels. A single, high dose of radiation is then delivered to the target area, minimizing damage to surrounding healthy tissue. The radiation causes damage to the endothelial cells lining the abnormal blood vessels, leading to their regression.
The STAR Trial: A Landmark Study: The recent Stereotactic Radiotherapy for nAMD (STAR) trial, published in The Lancet, demonstrated promising results for SRT as a treatment for nAMD.The trial involved patients who had previously responded to anti-VEGF therapy but required frequent injections to maintain their vision.
Key Findings of the STAR Trial: The STAR trial showed that a single session of SRT significantly reduced the need for anti-VEGF injections in many patients. A substantial proportion of patients were able to discontinue anti-VEGF injections altogether, while others experienced a significant reduction in injection frequency. Furthermore, the trial reported a favorable safety profile, with minimal long-term side effects.
SRT vs. Anti-VEGF: A Comparative Analysis
Understanding the differences between SRT and anti-VEGF therapy is crucial for informed treatment decisions.
Treatment Frequency: anti-VEGF requires frequent, ongoing injections, typically every 4-8 weeks. SRT, on the other hand, is a one-time treatment.
Mechanism of Action: Anti-VEGF drugs directly inhibit VEGF, a protein that promotes blood vessel growth. SRT indirectly reduces blood vessel activity by damaging endothelial cells.
Treatment Burden: The ongoing nature of anti-VEGF therapy represents a significant treatment burden for patients. SRT offers a perhaps more convenient and less invasive option.
Cost-Effectiveness: While the initial cost of SRT may be higher than a single anti-VEGF injection, the potential for reduced long-term injection costs could make SRT a more cost-effective option for some patients.
Efficacy: The STAR trial demonstrated comparable efficacy to anti-VEGF in terms of vision stabilization and improvement. Though, further research is needed to determine the long-term efficacy of SRT.
Potential Benefits of SRT For nAMD
Beyond reducing the need for frequent injections, SRT offers several potential benefits for patients with nAMD.
Reduced Treatment Burden: A single SRT session eliminates the need for ongoing injections, improving quality of life and reducing patient anxiety.
Potential for Long-Term Vision Stabilization: The STAR trial suggests that SRT can provide long-term vision stabilization, potentially preventing further vision loss.
**Alternative